Patent Issued for Coya’s IL-2 Technology

Coya Therapeutics has received a new U.S. patent for proprietary methods of producing a highly stable liquid formulation (aldesleukin) of recombinant human interleukin-2 (rhIL-2), according to a press release from the manufacturer.

The U.S. Patent and Trademark Office (USPTO) granted patent number US 12,312,389 B2, protecting novel production methods for aldesleukin-based ready-to-use (RTU) liquid formulations.

“The issuance of this in-licensed patent sets a strong milestone in the history of Coya,” said Arun Swaminathan, PhD, CEO of Coya Therapeutics, in the news release. “Our investigational low-dose rhIL-2 (COYA 301) is a key asset of Coya’s pipeline. This patent serves as only one component of a growing, broader, and layered IP portfolio involving combinations with other biologics—such as Coya’s combinations with CTLA-4 Ig (COYA 302) and GLP-1 agonists (COYA 303)—that we believe adds a broader moat of protection to the portfolio.”

Coya said that it is on track to submit an investigational new drug (IND) application for COYA 302 by the end of June 2025. COYA 301, COYA 302, and COYA 303 are investigational therapies and have not been approved by the U.S. Food and Drug Administration.

Source: Coya Theapeutics press release. June 3, 2025.